Weekly Respiratory Research Analysis
This week’s respiratory literature highlights rapid advances across prevention, antivirals, and oncology‑directed immunotherapy. A precision‑engineered STING nanoparticle adjuvant (NanoCF501) shows preclinical mucosal‑systemic pan‑β‑coronavirus protection and translational readiness. In oncology, a PD‑1/VEGF bispecific (ivonescimab) improves overall survival in post‑EGFR‑TKI EGFR‑variant NSCLC. Clinically relevant antiviral development is supported by a randomized human challenge showing oral RS
Summary
This week’s respiratory literature highlights rapid advances across prevention, antivirals, and oncology‑directed immunotherapy. A precision‑engineered STING nanoparticle adjuvant (NanoCF501) shows preclinical mucosal‑systemic pan‑β‑coronavirus protection and translational readiness. In oncology, a PD‑1/VEGF bispecific (ivonescimab) improves overall survival in post‑EGFR‑TKI EGFR‑variant NSCLC. Clinically relevant antiviral development is supported by a randomized human challenge showing oral RSV L‑protein inhibitor S‑337395 reduces viral load and symptoms with good tolerability.
Selected Articles
1. Precision-engineered STING agonist nanoparticles enable coordinated mucosal-systemic immunity for durable pan-β-coronavirus protection.
NanoCF501, a 2‑ethyl‑2‑oxazoline–formulated STING‑agonist nanoparticle, achieved efficient mucus penetration, localized respiratory retention, and induced strong mucosal (IgA) and systemic immunity with protection against homologous and heterologous β‑coronaviruses in mice and validation in non‑human primates. Single‑cell transcriptomics showed STING‑dependent reprogramming of lung APCs. The platform also repurposed licensed influenza antigens for intranasal delivery, indicating translational readiness.
Impact: Presents a broadly applicable mucosal adjuvant platform with multispecies validation and mechanistic insight, filling a critical gap for durable intranasal vaccination against coronaviruses and other respiratory pathogens.
Clinical Implications: If human safety and mucosal immunogenicity are confirmed, NanoCF501 could enable intranasal boosting or mucosal primary vaccines with reduced systemic reactogenicity—accelerating pandemic‑ready vaccine strategies.
Key Findings
- NanoCF501 achieved efficient mucus penetration and localized respiratory retention with minimal systemic exposure in rodents.
- Intranasal NanoCF501 plus multivalent coronavirus antigen induced robust mucosal (IgA) and systemic immunity, protecting against homologous and heterologous β‑coronaviruses.
- Single‑cell transcriptomics revealed STING‑dependent reprogramming of lung antigen‑presenting cells; efficacy signals were validated in non‑human primates and extended to licensed influenza antigens.
2. Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.
The phase 3 HARMONi‑A trial (N=322) found that adding ivonescimab (PD‑1/VEGF bispecific) to pemetrexed/carboplatin improved overall survival versus chemotherapy alone in EGFR‑variant nonsquamous NSCLC after prior EGFR‑TKI therapy (median OS 16.8 vs 14.1 months; HR 0.74; P=0.02). The 30‑month survival benefit and manageable safety profile suggest ivonescimab as a new option in a high‑need post‑TKI setting.
Impact: Demonstrates a survival advantage with a first‑in‑class bispecific PD‑1/VEGF antibody in a population with limited options after EGFR‑TKI failure, potentially changing subsequent‑line standards.
Clinical Implications: Ivonescimab plus pemetrexed/carboplatin should be considered where available for EGFR‑variant nonsquamous NSCLC after EGFR‑TKI progression; biomarker work (PD‑L1, VEGF axis) and broader population validation are needed.
Key Findings
- Median overall survival improved from 14.1 to 16.8 months with ivonescimab plus chemotherapy (HR 0.74; 95% CI 0.58–0.95; P=0.02).
- Estimated 30‑month survival: 29.1% (ivonescimab) vs 18.4% (placebo).
- Grade ≥3 treatment‑emergent adverse events were more frequent with ivonescimab (67.1% vs 54.7%).
3. Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the RSV L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection.
In a phase 2a randomized, double‑blind human challenge (n=114 randomized; 60 infected ITT), oral S‑337395 produced dose‑dependent reductions in RSV qRT‑PCR viral load AUC (30 mg and 300 mg reduced VL‑AUC by ~65% and ~89%, respectively) and viral culture, and the 300 mg dose reduced symptom AUC by ~78%. The drug was well tolerated, supporting progression to patient trials.
Impact: First randomized human challenge proof‑of‑concept showing an oral RSV L‑protein inhibitor yields robust antiviral and symptom benefit, advancing antiviral options beyond monoclonals and vaccines.
Clinical Implications: Supports rapid advancement of S‑337395 into larger patient populations (infants, older adults, comorbid patients) with endpoints such as time to recovery and hospitalization; offers potential for outpatient oral therapy for RSV.
Key Findings
- qRT‑PCR viral load AUC reduced by 64.87% (30 mg) and 88.94% (300 mg) versus placebo (both p<0.05).
- Viral culture AUC decreased by 72.32% (30 mg) and 86.17% (300 mg) versus placebo (both p<0.05).
- Total symptom score AUC was 78.15% lower at 300 mg (p<0.05); safety profile acceptable.